Furthermore, the utilization of PD-1 inhibitors (Nivolumab, Pembrolizumab) and PD-L1 inhibitors (Atezolizumab) has been endorsed by the U.S. Food and Drug Administration (FDA) in terms of patients’ treatments with advanced NSCLC experiencing disease progression in or post initial-line therapy due to their superior disease progression-free survival (PFS) and overall survival (OS) outcomes in comparison to the conventional chemotherapy comparator (3–6). Here, PDCD1 is linked to non-small cell lung carcinoma.